Ind-Swift Laboratories Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹150.85 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.17 per cent from ₹152.64 crore. This corresponds to a year-on-year *(YoY) growth of 17.12 per cent.
Operating Profit
Operating Profit stands at ₹-1.68 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 214.29 per cent from ₹1.47 crore. This corresponds to a year-on-year *(YoY) growth of 77.20 per cent.
PBDT
PBDT stands at ₹25.25 crore, reflecting a quarter-on-quarter *(QoQ) increase of 46.21 per cent from ₹17.27 crore. This corresponds to a year-on-year *(YoY) growth of 3,422.37 per cent.
Profit Before Tax
Profit Before Tax stands at ₹16.41 crore, reflecting a quarter-on-quarter *(QoQ) increase of 59.48 per cent from ₹10.29 crore. This corresponds to a year-on-year *(YoY) growth of 349.77 per cent.
Net Profit
Net Profit stands at ₹9.54 crore, reflecting a quarter-on-quarter *(QoQ) increase of 19.40 per cent from ₹7.99 crore. This represents a 273.77 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Ind-Swift Laboratories Ltd Earnings
- YOY
- QOQ
Ind-Swift Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Ind-Swift Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Ind-Swift Laboratories Ltd Financial Reports
Ind-Swift Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Ind-Swift Labs. | -0.40% | -4.29% | -0.75% | 1.80% | 34.48% | 84.95% |
| Shukra Pharma. | -4.99% | -9.93% | -6.66% | -24.55% | -28.92% | 138.61% |
| Syncom Formul. | -2.29% | -2.09% | 5.24% | 0.36% | -15.60% | -14.62% |
| Venus Remedies | 0.60% | 5.45% | -6.26% | 31.91% | 72.57% | 208.11% |
| Bajaj Healthcare | -1.33% | -10.32% | -9.84% | -15.82% | -32.71% | -45.67% |
| Themis Medicare | -3.01% | 2.16% | 23.68% | 12.31% | -14.33% | -23.02% |
| Wanbury | -2.33% | -0.97% | 2.88% | 0.29% | 2.18% | -5.04% |
Company Info
Company Information
Chairman / Executive Director / M D / Promoter : N R Munjal
ED / Joint MD / Promoter : Himanshu Jain
Executive Director : Rishav Mehta
Executive Director : Sahil Munjal
Independent Non Executive Women Director : Neerja Chathley
Independent Non Exe. Director : Rajinder Kumar Gupta
Independent Non Exe. Director : SUBODH GUPTA
Independent Non Exe. Director : Prabhat Khurana
VP / Company Secretary / Compliance Officer : Pradeep Verma